BIOMARIN PHARMACEUTICAL INC (BMRN) Stock
8 members of Congress disclosed 16 trades in BMRN since 2014: 8 purchases and 8 sales, most recently Daniel Goldman (sale, Mar 6, 2023). 8 of the hedge funds AlphaScala tracks reported BMRN in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Viking Global Investors's at $435.82M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 6, 2026.
Which members of Congress traded BIOMARIN PHARMACEUTICAL INC (BMRN)?
Most recent: Daniel Goldman (sale, Mar 6, 2023); records start Nov 14, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Goldman D-NY · House | 2023-03-06 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2021-10-18 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-12-30 | purchase | $15k – $50k |
| Josh Gottheimer D-NJ · House | 2020-10-16 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2019-12-11 | purchase | $1k – $15k |
| Alan Lowenthal D-CA · House | 2019-08-15 | sale | $1k – $15k |
| Alan Lowenthal D-CA · House | 2019-08-15 | sale | $506 |
| Van Taylor R-TX · House | 2019-03-25 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all BMRN political trades →Which hedge funds own BMRN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Viking Global Investors Andreas Halvorsen | 7.62M | $435.82M | +8% |
| Millennium Management Israel Englander | 2.07M | $118.55M | -31% |
| Citadel Ken Griffin | 1.12M | $64.22M | -75% |
| Renaissance Technologies Jim Simons (founder) | 452K | $25.86M | -56% |
| Bridgewater Associates Ray Dalio | 275K | $15.73M | +33% |
| Marshall Wace | 97K | $5.57M | NEW |
| D.E. Shaw David Shaw | 92K | $5.28M | -67% |
| Hussman Investment Trust John Hussman | 32K | $1.89M | NEW |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are BIOMARIN PHARMACEUTICAL INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 2, 26 | Davis George Eric | EVP, Chief Legal Officer | SELL | 17.6K | $1.2M |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →BMRN price chart
Powered by TradingViewWhat does BIOMARIN PHARMACEUTICAL INC do?
BioMarin Pharmaceutical Inc. is a leading global biotechnology company specializing in the development and commercialization of therapies for people with serious and life-threatening rare genetic diseases. Its portfolio includes eight approved treatments targeting conditions such as mucopolysaccharidosis types I, IVA, and VI (branded as Aldurazyme, Vimizim, and Naglazyme), phenylketonuria (Kuvan), achondroplasia (Voxzogo), Batten disease (Brineura), Lambert-Eaton myasthenic syndrome (Firdapse), and hemophilia A (Roctavian). These therapies encompass enzyme replacement therapies, gene therapies, and small molecule drugs designed to address the underlying genetic causes of these disorders. BioMarin Pharmaceutical Inc. operates in more than 70 countries across the United States, Europe, Latin America, the Middle East, and Asia Pacific, serving patient communities through innovative genetic science and molecular biology expertise. Founded in 1997 and headquartered in San Rafael, California, the company maintains a robust pipeline of clinical and preclinical candidates focused on skeletal dysplasias, liver diseases, and muscular dystrophies, reinforcing its pivotal role in the rare disease biotechnology sector.